As more evidence is accumulated on ATRX alterations in IDH-mutated gliomas [30], MGMTp methylation in general [28], and their impact on survival and progression in high-grade glioma patients, an increasing demand arises for studies elucidating the relationship between genetic mutations and improved early diagnosis. This evidence concerns the gene ATRX and central nervous system cancer.